Memo Therapeutics' Series A Round

Memo Therapeutics raised a round of funding on July 23, 2015.

Memo Therapeutics is an innovator in the area of recombinant immunoglobulins and human-derived monoclonal antibodies. The technological core of Memo Therapeutics is MemoMAB – a technology enabling c…

Articles about Memo Therapeutics' Series A Round: